Inflammation-Related Molecular Signatures Involved in the Anticancer Activities of Brigatinib As Well As the Prognosis of EML4-ALK Lung Adenocarcinoma Patient

Investigators systematically explored the validity of sequential ALK inhibitors for a heavy-treated patient with EML4-ALK fusion via developing an in vitro and in vivo drug testing system based on patient-derived models.